---
document_datetime: 2025-05-06 18:31:38
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ocrevus-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ocrevus-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.3399279
conversion_datetime: 2025-12-20 11:51:23.139178
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ocrevus

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| X/0039               | Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration | 25/04/2024                          | 20/06/2024                                  | SmPC, Labelling and PL           |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0036/G   | This was an application for a group of variations.   | 20/04/2023   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

| product - Other changes (including replacement B.II.d.2.d - Change in test product - Other changes (including replacement B.II.d.2.d - Change in test product - Other changes (including replacement B.II.d.2.d - Change in test product - Other changes (including replacement B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.II.d.2.d - Change in test product - Other changes (including replacement B.I.b.1.z - Change in the and/or limits of an AS, material/intermediate/reagent B.II.d.1.z - Change in the and/or limits of the finished B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits B.II.d.1.a - Change in the and/or limits of the finished specification limits   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |            |                   |                                                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035/G | This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a                                                                                      | 30/03/2023 | 27/03/2024 | SmPC and Annex II | SmPC section 9 has been updated with the date of the latest renewal. Annex II has been updated to include Roche Singapore Technical Operations, Pte. Ltd, 10 Tuas Bay Link, 637394 Singapore as alternative site responsible for manufacture of active substance. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | biological/immunological product - Change in the manufacturer of AS or of a material/reagent/intermediate for AS - to quality control testing arrangements for AS -replacement or addition of a site where control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     | B.I.a.1.f starting Changes the batch   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------|
| II/0034/G | This was an application for a group of variations. Submission of the final report from study BN29739 (VELOCE) listed as a category 3 study in the RMP. This is a phase 3b, multicentre, randomized, parallel- group, open-label study to evaluate the effectiveness of vaccinations in patients with relapsing forms of multiple sclerosis (RMS) undergoing treatment with ocrelizumab. Submission of the final report from studies MA30005 (CASTING) and MN30035 (CHORDS). These are prospective, multicenter, international, interventional, open-label phase 3b studies to assess the efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment. The RMP version 8.0 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 16/03/2023 | n/a |                                        |

<div style=\"page-break-after: always\"></div>

|                     | elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |                                  |                                                                                                                                                                                                                                                                       |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0037              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                           | 15/03/2023 | 27/03/2024 | PL                               |                                                                                                                                                                                                                                                                       |
| R/0033              | Renewal of the marketing authorisation.                                                                                                                                                                                                    | 21/07/2022 | 21/09/2022 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ocrevus in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IG/1496             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                              | 18/03/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| N/0031              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                           | 03/02/2022 | 21/09/2022 | Labelling and PL                 |                                                                                                                                                                                                                                                                       |
| PSUSA/10662 /202103 | Periodic Safety Update EU Single assessment - ocrelizumab                                                                                                                                                                                  | 28/10/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| IB/0029             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                               | 05/10/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| IB/0028             | B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test                                                                                   | 13/08/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| IA/0026/G           | This was an application for a group of variations.                                                                                                                                                                                         | 10/06/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0025 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                            | 20/04/2021 | 03/12/2021 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                   |
| II/0024 | Update of section 4.4 of the SmPC to amend the wording on progressive multifocal leukoencephalopathy (PML) as requested in the conclusions of the latest periodic safety update report single assessment (PSUSA) procedure (PSUSA/00010662/202003) adopted in November 2020. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                            | 09/04/2021 | 03/12/2021 | SmPC        | The warning in section 4.4 of the SmPC on Progressive Multifocal Leukoencephalopathy (PML) is updated to include lymphopenia and advanced age as new risk factors for PML present in the ocrelizumab-treated patient who developed PML without prior disease-modifying therapy use. For more information, please refer to the Summary of Product Characteristics. |
| II/0023 | Update of the SmPC Section 5.1 with the newly available post-hoc analysis results related to the time-to-wheelchair data performed on clinical study WA25046 (ORATORIO) in the PPMS population.                                                                                                                                                                                                                                                                                                                           | 04/03/2021 | 03/12/2021 | SmPC        | Given the established and observed clinical efficacy and safety profile for ocrelizumab, the exploratory analyses from controlled and open label extended periods of pivotal study for confirming efficacy and safety of ocrelizumab in                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                 |            |            |                   | early PPMS are considered as not statistically compelling. However, acknowledging the difficulties to demonstrate efficacy for disability long-term endpoints, even with the mentioned caveats, the CHMP agreed to include a brief and balanced summary of the 24W-CDP analysis in ECP in Section 5.1 of the SmPC. For more information, please refer to the Summary of Product Characteristics.                          |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021             | Update of sections 4.4 and 4.8 in order to include the term 'anaphylaxis' among the possible symptoms of infusion-related reactions (IRRs), following an analysis of cases retrieved by anaphylactic reaction MedDRA narrow SMQ. The MAH took the opportunity to update Annex II.C and D in line with the QRD template. The RMP version 7.0 has been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 11/02/2021 | 03/12/2021 | SmPC and Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10662 /202003 | Periodic Safety Update EU Single assessment - ocrelizumab                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/11/2020 | 11/01/2021 | SmPC and PL       | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10662/202003.                                                                                                                                                                                                                                                                                |
| II/0020             | Update of section 5.3 of the SmPC in order to update information on embryo-fetal and pre- and postnatal development in cynomolgus monkeys based on final results from study 17-1133 listed as a Category 3 study in the RMP (MEA 006). The RMP v. 5.0 has also been submitted. C.I.13 - Other variations not specifically covered                                                                                                                                                 | 26/11/2020 | 03/12/2021 | SmPC              | SmPC new text Section 5.3 is updated to include results from study 17- 1133 assessing embryo-fetal and pre- and postnatal development in cynomolgus monkeys. As a consequence of this variation, mortality and causes of mortality in this non- clinical study are included in the section 5.3 of the SmPC. The safety margin was revised because these events occurred at a lower dose as compared to the previous study |

<div style=\"page-break-after: always\"></div>

|             | elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             | (06-1260). For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0022/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                  | 18/11/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0017     | To update sections 4.2, 4.8 and 5.1 of the SmPC to add the option of a shorter infusion for second and subsequent doses of Ocrevus (2 hours, compared to the approved 3.5 hours infusion) based on the primary analysis of a therapeutic use substudy, MA30143 Shorter Infusion Substudy (Ensemble Plus). The Package Leaflet is updated accordingly. The RMP has been updated (ver. 4.0) with regards to the inclusion of shorter infusion duration (Part I Product Overview), the clinical trial exposure (Part II Module SIII) and the identified risk of infusion- related reactions (Part II Module SVII). C.I.4 - Change(s) in the SPC, Labelling or PL due to | 30/04/2020 | 11/01/2021 | SmPC and PL | With this variation the MAH proposes a 2 hour infusion duration, as an alternative to the 3.5 hour infusion duration, from the second dose and onwards, based on the primary analysis of a therapeutic use substudy, MA30143 Shorter Infusion Substudy (Ensemble Plus) designed to characterise the safety profile of shorter Ocrevus infusions in patients with Relapsing-Remitting Multiple Sclerosis. For more information, please refer to the Summary of Product Characteristics, sections 4.2, 4.8 and 5.1. |

<div style=\"page-break-after: always\"></div>

|                     | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                        | 17/04/2020 | 11/01/2021 | SmPC and PL |                                                                                                                                            |
| PSUSA/10662 /201909 | Periodic Safety Update EU Single assessment - ocrelizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/04/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| IB/0016             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/02/2020 | n/a        |             |                                                                                                                                            |
| PSUSA/10662 /201903 | Periodic Safety Update EU Single assessment - ocrelizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/10/2019 | 16/12/2019 | SmPC        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10662/201903. |
| II/0014/G           | This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.d - Change in test procedure for AS or | 12/09/2019 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range   |            |            |      |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0013             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/09/2019 | n/a        |      |                                                                                                                                            |
| PSUSA/10662 /201809 | Periodic Safety Update EU Single assessment - ocrelizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/04/2019 | 20/06/2019 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10662/201809. |
| IB/0011             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 15/05/2019 | n/a        |      |                                                                                                                                            |
| IA/0010/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/02/2019 | n/a        |      |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0008 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/01/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0007 | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                                                                                                                                                          | 22/11/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0002 | Update of sections 4.4, 4.5, 4.6 and 5.1 of the SmPC in order to include information on vaccination based on interim results from study BN29739 listed as a category 3 study in the RMP; this is a phase IIIb, multicentre, randomised, parallel-group, open-label study to evaluate the effects of ocrelizumab on immune response in patients with relapsing forms of multiple sclerosis. The Package Leaflet is updated accordingly. The RMP version 2.3 has also been submitted. Furthermore, the MAH took the opportunity to implement a minor editorial change in section 6.6 of the SmPC with regards to instructions for dilution. | 31/10/2018 | 20/06/2019 | SmPC and PL | In a randomized open-label study, patients with relapsing forms of multiple sclerosis (RMS) were able to mount humoral responses, although decreased, to tetanus toxoid, 23-valent pneumococcal polysaccharide with or without a booster vaccine, keyhole limpet hemocyanin neoantigen, and seasonal influenza vaccines. The percentage of patients with a positive response to tetanus vaccine at 8 weeks after vaccination was 23.9% in the ocrelizumab group compared to 54.5% in the control group (no disease- modifying therapy except interferon-beta). Geometric mean anti-tetanus toxoid specific antibody titers at 8 weeks were 3.74 and 9.81 IU/ml, respectively. Positive response to  5 serotypes in 23-PPV at 4 weeks after vaccination was |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | 71.6% in the ocrelizumab group and 100% in the control group. In patients treated with ocrelizumab a booster vaccine (13-PCV) given 4 weeks after 23-PPV did not markedly enhance the response to 12 serotypes in common with 23-PPV. The percentage of patients with seroprotective titers against five influenza strains ranged from 20.0  60.0% and 16.7  43.8% pre-vaccination and at 4 weeks post vaccination from 55.6  80.0% in patients treated with ocrelizumab and 75.0  97.0% in the control group, respectively. It is recommended to vaccinate patients treated with Ocrevus with seasonal influenza vaccines that are inactivated. Due to the potential depletion of B cells in infants of mothers who have been exposed to Ocrevus during pregnancy, vaccination with live or live-attenuated vaccines should be delayed until B-cell levels have recovered; therefore, measuring CD19-positive B-cell levels, in neonates and infants, prior to vaccination is recommended. All vaccinations other than live or live- attenuated should follow the local immunisation schedule and measurement of vaccine-induced response titers should be considered to check whether individuals have mounted a protective immune response because the efficacy of the vaccination may be decreased. Postponing vaccination with live or live-attenuated vaccines   |
|---------------------|---------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10662 /201803 | Periodic Safety Update EU Single assessment - ocrelizumab                                                           | 04/10/2018 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0004             | B.II.g.2 - Introduction of a post approval change                                                                   | 20/09/2018 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | protocol related to the finished product                                                                                   |            |            |                        | management   |
|---------|----------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------|
| IB/0005 | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 23/08/2018 | n/a        |                        |              |
| N/0006  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 09/08/2018 | 20/06/2019 | PL                     |              |
| T/0001  | Transfer of Marketing Authorisation                                                                                        | 20/02/2018 | 23/03/2018 | SmPC, Labelling and PL |              |